An expert panel of India’s drug regulator has recommended relaxing norms for the use of a government-backed coronavirus vaccine after it was found to be highly effective in a late-stage trial, the regulator said on its website on Thursday.
“After detailed deliberation, the committee recommended for omission of the condition of the use of the vaccine in clinical trial mode,” the Central Drugs Standard Control Organization said. “However, the vaccine should be continued to be used under restricted use in emergency situation condition.”
Bharat Biotech’s vaccine showed an 81 percent efficacy in preventing symptomatic COVID-19 in an interim analysis of a late-stage trial in India, it said last week.
- Pfizer seeks to make vaccine in India if assured of faster clearance, export freedom
- India seeks investment for vaccine production to match China’s push-source
- Indian vaccine giant Serum Inst. warns of supply hit from US raw materials export ban
- Indian firm Bharat Biotech’s COVID-19 vaccine 81 pct effective, shows interim data